Preparation method and non-classical antibacterial activity application of 1-methyl-4-phenyl ether derivative
By developing inhibitors based on the LsrK/HPr PPI site to regulate bacterial AI-2 quorum sensing, the problems of poor activity and drug resistance of existing AI-2 quorum sensing modulators in Gram-negative bacteria have been solved, enabling effective treatment of both Gram-positive and Gram-negative bacteria.
Patent Information
- Application Number
- CN202310566269.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-22
AI Technical Summary
Existing AI-2 quorum sensing modulators exhibit poor activity and high toxicity in Gram-negative bacteria, and are easily deactivated by drug-resistant efflux pumps, making them ineffective in treating multidrug-resistant bacterial infections.
Develop inhibitors based on the LsrK/HPr PPI site to reduce bacterial pathogenicity by modulating bacterial AI-2 quorum sensing, for the treatment of infections caused by Gram-positive and Gram-negative bacteria.
It effectively reduces bacterial pathogenicity, increases the sensitivity of antimicrobial peptides, reduces bacterial invasion and adhesion, and provides therapeutic effects against multidrug-resistant bacteria.
Smart Images

Figure CN118994022A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical chemical industry, and specifically relates to the preparation of novel bacterial AI-2 quorum sensing regulators and their use in treating bacterial infection-related diseases caused by bacterial quorum sensing and pharmaceutical compositions containing the same. Background Art
[0002] Quorum sensing (QS) is a communication mechanism in which bacteria use signal molecules to communicate within or between species. Bacteria sense the concentration of signal molecules in the surrounding environment and determine the bacterial density to regulate the production of virulence factors, antibiotic sensitivity, motility, biofilm formation and other phenotypes of the bacterial population. Bacterial quorum sensing regulators (QSIs) can reduce the pathogenicity of bacteria without inhibiting bacterial growth and are not prone to drug resistance. Therefore, they are considered to be a new type of antibiotic that can treat multidrug-resistant bacterial infections. Among the currently known quorum sensing, only AI-2 quorum sensing exists between Gram-positive bacteria and Gram-negative bacteria at the same time, and is the "universal language" for bacterial interspecies communication. However, existing AI-2 quorum sensing regulators have problems such as poor activity, high toxicity, and poor drug-likeness. In addition, multidrug resistance efflux pumps, especially the resistant nodule cell division (RND) family, cause existing AI-2 quorum sensing regulators to fail in Gram-negative bacteria.
[0003] LsrK is an important member of AI-2 quorum sensing, which is responsible for phosphorylating (S)-DPD to P-DPD, which is necessary for activating the lsr operon. At the same time, lsrK gene knockout results in the inability of AI-2 quorum sensing to be positively regulated. When LsrK binds to HPr (an important member of the bacterial phosphotransferase system) allosterically, its phosphorylation function is significantly inhibited. The inhibitors discovered based on the LsrK / HPr PPI site involved in the present invention can inhibit bacterial AI-2 quorum sensing, bacterial motility, increase antimicrobial peptide sensitivity, reduce bacterial invasion and adhesion, and affect bacterial biofilm formation, and are considered to be promising for further development as new antibiotics.
[0004] The AI-2 quorum sensing modulator of the present invention can be used to treat various diseases including but not limited to endocarditis, peritonitis, gastroenteritis, cholecystitis, cystitis, diarrhea, empyema, sepsis, etc. caused by Gram-positive bacteria or Gram-negative bacteria such as Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae, Proteus, Shigella, Brucella, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Acinetobacter, Yersinia, Pasteurella, Shigella, Bordetella pertussis, Bordetella parapertussis, Bacillus parahaemolyticus, Legionella pneumophila, Vibrio cholerae, etc. It is particularly suitable for the treatment of diseases caused by drug-resistant Gram-negative bacteria that are insensitive to existing antibiotics.
[0005] The purpose of the present invention is to prepare a novel bacterial AI-2 quorum sensing regulator for use in the treatment of diseases caused by Gram-positive bacteria or Gram-negative bacteria. Summary of the invention
[0006] One of the purposes of the present invention is to provide a compound, its isomers, its pharmaceutically acceptable salts and solvates thereof, which can reduce bacterial pathogenicity and treat related diseases caused by bacterial infection by regulating bacterial AI-2 quorum sensing.
[0007] To achieve the above-mentioned object, the first aspect of the present invention provides a compound represented by Formula I, its isomers, its pharmaceutically acceptable salts and solvates thereof;
[0008]
[0009] in,
[0010] A is an O or S atom;
[0011] R 1 is a substituted or unsubstituted aromatic carbocyclic ring, aromatic heterocyclic ring, aromatic condensed ring or aromatic heterocondensed ring containing 5 to 10 atoms; wherein the aromatic carbocyclic ring, aromatic heterocyclic ring, aromatic condensed ring or aromatic heterocondensed ring is optionally selected from the following mono- or poly-substituted: substituted or unsubstituted straight-chain or branched alkyl, halogen, cyano, amino, trifluoromethyl, hydroxyl, alkoxy, carboxyl, ester, phosphoester, phosphate;
[0012] R 2 is a 5- to 8-membered substituted or unsubstituted heterocyclic ring containing O, N, and S atoms; or is a substituted or unsubstituted aromatic heterocyclic ring or aromatic heterocondensed ring containing 5 to 10 atoms; wherein the saturated or unsaturated heterocyclic ring, aromatic heterocyclic ring, and aromatic heterocondensed ring are optionally selected from the following mono- or poly-substituted: substituted or unsubstituted straight-chain or branched alkyl, halogen, cyano, amino, trifluoromethyl, hydroxyl, alkoxy, carboxyl, ester, phosphoester, and phosphate;
[0013] X 1 is a F, Cl, Br atom, an alkoxy group, an alkyl group with 1 to 3 carbon atoms;
[0014] X 2 is a F, Cl, Br atom, an alkoxy group, an alkyl group with 1 to 3 carbon atoms;
[0015] The aromatic carbon ring is selected from the group consisting of benzene, naphthalene, anthracene, phenanthrene, indene, fluorene and acenaphthene;
[0016] The aromatic heterocycle is selected from the group consisting of pyridine, pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, oxazole, isoxazole, indole, benzofuran, carbazole, pyridazine, pyrazine, quinoline, isoquinoline, purine, phenothiazine, and phenoxazine;
[0017] Structural formula I includes its racemate or optical isomer, and pharmaceutically acceptable salts and solvates thereof.
[0018] In a specific embodiment of the present invention, the compound of formula 1, its solvate, or its pharmaceutically or physiologically acceptable salt, wherein the compound is selected from:
[0019] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0020] 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-1H-1,2,4-triazole
[0021] N-(4-(Naphthalen-2-ylmethoxy)benzyl)-1-(pyridin-3-yl)methanamine
[0022] 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-1H-imidazole
[0023] 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-5-nitro-1H-imidazole
[0024] N-(4-(Naphthalen-1-ylmethoxy)benzyl)pyrazin-2-amine
[0025] N-Methyl-N-(4-(naphthalen-2-ylmethoxy)benzyl)pyridin-3-amine
[0026] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-5-nitro-1H-imidazole
[0027] N-(4-(Naphthalen-2-ylmethoxy)benzyl)pyridin-3-amine
[0028] 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0029] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0030] 1-(3-methyl-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0031] 1-(3-methoxy-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0032] 1-(4-((2,4-di-tert-butylbenzyl)oxy)benzyl)-1H-imidazole
[0033] 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole
[0034] 1-(3-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0035] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole
[0036] 1-(4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0037] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-tetrazolyl
[0038] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-tetrazolyl
[0039] 1-(2-Fluoro-4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0040] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0041] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0042] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0043] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester
[0044] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid
[0045] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid
[0046] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0047] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0048] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid
[0049] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid
[0050] 1-(3-fluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0051] 3-(4-((3-fluoro-5-(trifluoromethyl)benzyl)oxy)benzyl)-4H-4-imidazole-5-carboxylic acid methyl ester
[0052] 1-(3-Fluoro-4-(perfluorophenyl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0053] 1-(3-fluoro-4-((3-fluoro-3-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0054] 1-(4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0055] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0056] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0057] 1-(4-((2-bromo-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0058] 1-(4-((4-fluoronaphthalen-1-yl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0059] 1-(4-(Cyclohexylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0060] N 1 -(4-(Naphthalen-2-ylmethoxy)benzyl)ethane-1,2-diamine
[0061] N-(4-(Naphthalen-2-ylmethoxy)benzyl)piperidin-4-amine
[0062] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)azetidin-3-amine
[0063] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid butyl ester
[0064] 2-(2-methoxyethoxy)ethoxyethyl-1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylate
[0065] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid hexan-2-yl ester
[0066] Isopropyl 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylate
[0067] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid propyl ester
[0068] 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole
[0069] 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0070] 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0071] 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid butyl ester
[0072] 1-(4-((6-bromonaphthalen-2-yl)methoxy)benzyl)-1H-imidazole
[0073] 1-(4-((6-ethylnaphthyl-2-yl)methoxy)benzyl)-1H-imidazole
[0074] (1H-imidazol-4-yl)(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)methanol
[0075] 4-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0076] 4-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0077] Its pharmaceutically acceptable salt or solvate.
[0078] A pharmaceutical composition comprising at least one compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and one or more pharmaceutically acceptable carriers or excipients.
[0079] The compound represented by formula I is used for preparing drugs for preventing and / or treating diseases caused by bacterial quorum sensing.
[0080] The compounds of the present invention can be prepared by the following reaction routes:
[0081]
[0082] Among them, A, X 1 , X 2 , R 1 , R 2 The definition is the same as the general formula I described in claim 1. DETAILED DESCRIPTION OF THE INVENTION
[0084] As used herein, the term "aromatic carbocycle" has its general meaning as known in the art, which forms part of the group in the compounds of general formula I, and which generally includes, but is not limited to: benzene, naphthalene, anthracene, phenanthrene, indene, fluorene, acenaphthene, which may be optionally substituted singly or multiple times.
[0085] As used herein, the term "aromatic heterocycle" has its general meaning as known in the art, which forms part of the group in the compounds of general formula I and which generally includes, but is not limited to, pyridine, pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, oxazole, isoxazole, indole, benzofuran, benzimidazole, carbazole, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline, purine, phenothiazine, phenoxazole, which may be optionally substituted singly or multiple times.
[0086] As used herein, the term "aromatic fused ring" has its general meaning as known in the art, which forms part of the group in the compounds of Formula I, and which generally includes, but is not limited to, the examples of aromatic fused rings listed herein.
[0087] As used herein, the term "aromatic fused heterocycle" has its general art-recognized meaning that forms part of the radical in the compounds of Formula I, and generally includes, but is not limited to, the examples of aromatic fused heterocycles listed herein.
[0088] As used herein, the term "alkyl" has its ordinary meaning known in the art, and generally includes straight or branched chain alkyl groups, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, and the like.
[0089] As used herein, the term "halogen" has its ordinary meaning as known in the art, and generally includes F, Cl, Br, I, and may also include isotopic forms thereof.
[0090] As used herein, the groups represented by the following terms have their general meanings as known in the art: nitrile, trifluoromethyl, trifluoromethoxy, hydroxy, nitro, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxyacyl, carboxyamidoalkyl, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfamoyl, amidino, cyano, amino, amido, alkylamino, dialkylamino, alkylaminoalkyl;
[0091] As used herein, the phrase "a five- to eight-membered substituted or unsubstituted heterocyclic ring containing O, N, or S atoms" has its general meaning known in the art, and may also specifically refer herein to carbon atoms on the ring being substituted with said O, N, or S.
[0092] According to the present invention, the compound of the general formula I can be prepared by the following typical exemplary method, which comprises the following steps:
[0093] 1. Add R to the round bottom flask1 , potassium carbonate, 2-(bromomethyl)naphthalene, condense and reflux at 60°C for 3 hours, remove acetonitrile by vacuum rotary evaporation, slurry the residue with water: acetonitrile = 50:1, collect the precipitate by filtration, and dry in vacuum to obtain white solid intermediate 1.
[0094]
[0095] Among them, A, R 1 , X 1 , X 2 The definition is the same as the general formula I described in claim 1.
[0096] 2. Add intermediate 1 and methanol to a round-bottom flask, and slowly add NaBH in an ice bath (0°C). 4 The mixture was stirred for about 0.5 hours, and the internal temperature was kept below 5° C. After the reaction was completed, the mixture was quenched with saturated sodium bicarbonate solution, methanol was removed by rotary evaporation, water was added for slurrying, and the precipitate was collected by filtration and dried in vacuo to obtain intermediate 2.
[0097]
[0098] Among them, A, R 1 , X 1 , X 2 The definition is the same as the general formula I described in claim 1.
[0099] 3. Add intermediate 2 to a two-necked flask, place in an ice bath (0°C), under nitrogen protection, add ultra-dry dichloromethane and stir until the solid is dissolved; 3 Slowly add dropwise to the reaction system, slowly warm to room temperature and react for about 1 hour after the addition is completed. After the reaction is completed, the reaction mixture is poured into a saturated sodium bicarbonate solution to quench and the pH of the aqueous phase is maintained at 7-8. DCM is removed by rotary evaporation at 27°C, the product precipitates, and is filtered and washed with PE (10 mL×3) and the precipitate is collected to obtain intermediate 3.
[0100]
[0101] Among them, A, R 1 , X 1 , X 2 The same as the definition of the general formula I in claim 1
[0102] 4. Add intermediate 3, acetonitrile, R 2 and potassium carbonate, heated at 60°C for 3 hours under condensation reflux. After the reaction is complete, the mixture is cooled to room temperature and concentrated under pressure. The residue is separated by column chromatography to obtain the target compound.
[0103]
[0104] Among them, A, R1 , R 2 , X 1 , X 2 The definition is the same as the general formula I described in claim 1. DETAILED DESCRIPTION
[0105] The present invention is further described below by means of specific intermediates and examples. However, it should be understood that these intermediates and examples are only used for more detailed and specific description and should not be construed as limiting the present invention in any form.
[0106] The present invention provides a general and / or specific description of the materials and test methods used in the test. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible. It is clear to those skilled in the art that, hereinafter, unless otherwise specified, the materials and operating methods used in the present invention are well known in the art.
[0107] 1 H-NMR spectra were measured by AVANCE NEO 600M nuclear magnetic resonance instrument, and mass spectra were measured by API 3000 triple quadrupole tandem mass spectrometer.
[0108] [Example 1] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0109] 1.1 [Preparation of Intermediate 1] 4-(Naphth-2-ylmethoxy)benzaldehyde
[0110]
[0111] 4-Hydroxybenzaldehyde (4.40 g, 0.036 mol) and K 2 CO 3 (9.95 g, 0.072 mol) was dissolved in acetonitrile (120 mL), 2-(bromomethyl)naphthalene (8.00 g, 0.036 mol) was added and condensed and refluxed at 60° C. for 3 hours. After TLC monitoring, most of the acetonitrile was removed by vacuum rotary evaporation, and the residue was slurried with water (100 mL): acetonitrile (2 mL) = 50:1, and the precipitate was collected by filtration and dried in vacuo to obtain 8.61 g of a white solid, with a yield of 91.22%.
[0112] ESI-MS (m / z): 263.11 [M+H] + .
[0113] 1 H NMR (600 MHz, DMSO-d 6)δppm: 9.87 (s, 1H), 8.01 (d, J=1.6Hz, 1H), 7.96 (d, J=8.5Hz, 1H), 7.95-7.92 (m, 2H), 7.91-7 .86 (m, 2H), 7.60 (dd, J=8.4, 1.7Hz, 1H), 7.57-7.50 (m, 2H), 7.29-7.24 (m, 2H), 5.41 (s, 2H).
[0114] 1.2 [Preparation of Intermediate 2] (4-(naphthalen-2-ylmethoxy)phenyl)methanol
[0115]
[0116] 4-(Naphthalen-2-ylmethoxy)benzaldehyde (9.00 g, 0.034 mol) was dissolved in methanol (160 mL) and NaBH was slowly added under ice bath condition (0 °C). 4 (0.96 g, 0.038 mol) and stirred for about 0.5 hours, keeping the internal temperature below 5 ° C. After the reaction was completed by TLC monitoring, the reaction system was quenched with saturated sodium bicarbonate solution until no bubbles were generated. Most of the methanol was removed by rotary evaporation, and water (100 mL) was added for pulping. The precipitate was collected by filtration and vacuum dried to obtain 8.56 g of a white solid, with a yield of 94.35%.
[0117] ESI-MS (m / z): 287.10 [M+Na] + .
[0118] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.97 (d, J=1.7Hz, 1H), 7.95-7.91 (m, 3H), 7.57 (dd, J=8.4, 1.7Hz, 1H), 7. 55-7.50 (m, 2H), 7.26-7.21 (m, 2H), 7.04-6.98 (m, 2H), 5.26 (s, 2H), 4.41 (s, 2H).
[0119] 1.3 [Preparation of Intermediate 3] 2-((4-(bromomethyl)phenoxy)methyl)naphthalene
[0120]
[0121] Weigh (4-(naphthalen-2-ylmethoxy)phenyl)methanol (2.00 g, 0.0076 mol) into a two-necked flask. 2 After protection, add ultra-dry dichloromethane (20 mL) and stir in an ice bath (0°C) until the solid dissolves; draw PBr by syringe 3(1 mL) was slowly added dropwise to the reaction system, and the temperature was slowly raised to room temperature for about 1 hour. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution to quench and the pH of the aqueous phase was maintained at 7-8. 2 Cl 2 The phase was evaporated at 27 °C to remove most of the CH 2 Cl 2 The product precipitated, was filtered and washed with PE (10 mL×3), and the precipitate was collected and used for the next reaction without purification.
[0122] [Preparation of Example 1] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0123]
[0124] To an acetonitrile (40 mL) solution were added 2-((4-(bromomethyl)phenoxy)methyl)naphthalene (0.40 g, 1.22 mmol), imidazole (0.10 g, 1.46 mmol) and K in sequence at room temperature. 2 CO 3 (0.34 g, 2.44 mmol), then heated to 60°C and stirred for 3 hours. After the reaction was completed by TLC monitoring, the mixture was cooled to room temperature, concentrated in vacuo to remove most of the acetonitrile solution, 100 mL of water was added to the residue and CH 2 Cl 2 Extract three times (60 mL × 3). Combine the organic phases and wash with saturated brine (180 mL × 3), anhydrous MgSO 4 The residue was purified by column chromatography (0% to 8% MeOH / CH 2 Cl 2 ) to obtain a white powdery solid, yield: 35.42%.
[0125] ESI-HRMS (m / z): 315.1492 [M+H] + .
[0126] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.98-7.89 (m, 4H), 7.73 (s, 1H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.55-7.49 (m, 2H), 7 .26-7.20(m,2H),7.15(s,1H),7.07-7.01(m,2H),6.88(s,1H),5.26(s,2H),5.1O(s,2H).
[0127] [Example 2] 1-(4-(naphthalen-1-ylmethoxy)benzyl)-1H-1,2,4-triazole
[0128]
[0129] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-1,2,4-triazole is used instead of imidazole and 1-(bromomethyl)naphthalene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 28.88%.
[0130] ESI-HRMS (m / z): 316.1446 [M+H] + .
[0131] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.60 (s, 1H), 7.98-7.89 (m, 5H), 7.59-7.49 (m, 3H), 7.28-7.22 (m, 2H), 7.07-7.02 (m, 2H), 5.32 (s, 2H), 5.26 (s, 2H).
[0132] [Example 3] N-(4-(naphthalen-2-ylmethoxy)benzyl)-1-(pyridin-3-yl)methylamine
[0133]
[0134] The synthesis method is similar to that described in 1.4 of Example 1, except that pyridine-3-methylamine is used instead of imidazole to obtain a white powdery solid with a yield of 31.48%.
[0135] ESI-HRMS (m / z): 355.1806 [M+H] + .
[0136] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.51 (d, J=2.0Hz, 1H), 8.43 (dd, J=4.8, 1.7Hz, 1H), 8.01-7.89 (m, 4H), 7.74 (dt, J=7.9, 2.0Hz, 1H), 7.58 (dd, J=8.4, 1.7Hz, 1H), 7.56-7.49(m, 2H), 7.33(dd, J=7.8, 4.7Hz, 1H), 7.29-7.23(m, 2H), 7.04-6.97(m, 2H), 5.26(s, 2H), 3.67(s, 2H), 3.61(s, 2H).
[0137] [Example 4] 1-(4-(naphthalen-1-ylmethoxy)benzyl)-1H-imidazole
[0138]
[0139] The synthesis method is similar to that described in 1.4 of Example 1, except that 1-(bromomethyl)naphthalene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 42.87%.
[0140] ESI-HRMS (m / z): 315.1492 [M+H] + .
[0141] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.10-8.04 (m, 1H), 8.00-7.95 (m, 1H), 7.93 (d, J = 8.2Hz, 1H), 7.76 (s, 1H), 7.66 (d, J = 6.9Hz, 1H), 7.60-7.52 ( m, 2H), 7.54-7.48 (m, 1H), 7.28-7.23 (m, 2H), 7.18 (s, 1H), 7.11-7.06 (m, 2H), 6.89 (s, 1H), 5.53 (s, 2H), 5.12 (s, 2H).
[0142] [Example 5] 1-(4-(naphthalen-1-ylmethoxy)benzyl)-4-nitro-1H-imidazole
[0143]
[0144] The synthesis method is similar to that described in 1.4 of Example 1, except that 5-nitro-1H-imidazole is used instead of imidazole and 1-(bromomethyl)naphthalene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 36.17%.
[0145] ESI-HRMS(m / z):382.1164[M+Na] + .
[0146] 1 H NMR (600 MHz, DMSO-d 6)δppm: 8.47 (d, J=1.4Hz, 1H), 8.08-8.05 (m, 1H), 8.00-7.96 (m, 2H), 7.93 (d, J=8.2Hz, 1H), 7.66 (dd, J=7.1, 1.2Hz, 1 H), 7.59-7.54 (m, 2H), 7.51 (dd, J=8.3, 7.0Hz, 1H), 7.42-7.36 (m, 2H), 7.15-7.07 (m, 2H), 5.54 (s, 2H), 5.23 (s, 2H).
[0147] [Example 6] N-(4-(naphthalen-1-ylmethoxy)benzyl)pyrazine-2-amine
[0148]
[0149] The synthesis method is similar to that described in 1.4 of Example 1, except that pyrazine-2-amine is used instead of imidazole and 1-((4-(bromomethyl)phenoxy)methyl)naphthalene is used instead of 2-((4-(bromomethyl)phenoxy)methyl)naphthalene to obtain a white powdery solid. Yield: 30.11%
[0150] ESI-HRMS(m / z):342.1602[M+Na] + .
[0151] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.97 (d, J=1.6Hz, 1H), 7.95-7.89 (m, 5H), 7.64 (d, J=2.9Hz, 1H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.55-7 .49 (m, 2H), 7.47 (t, J=5.9Hz, 1H), 7.29-7.23 (m, 2H), 7.04-6.98 (m, 2H), 5.26 (s, 2H), 4.39 (d, J=5.9Hz, 2H).
[0152] [Example 7] N-methyl-N-(4-(naphthalen-1-ylmethoxy)benzyl)pyridin-3-amine
[0153]
[0154] The synthesis method is similar to the method described in 1.4 of Example 1, except that N-methylpyridin-3-amine is used instead of imidazole to obtain a white powdery solid with a yield of 23.63%.
[0155] ESI-HRMS (m / z): 355.1805 [M+H] +
[0156] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.09-8.05 (m, 1H), 8.01-7.88 (m, 4H), 7.59-7.45 (m, 4H), 7.14 (d, J=8.6Hz, 2 H), 6.99 (d, J=8.6Hz, 2H), 6.64-6.52 (m, 2H), 5.23 (s, 2H), 4.70 (s, 2H), 2.97 (s, 3H).
[0157] [Example 8] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-4-nitro-1H-imidazole
[0158]
[0159] The synthesis method is similar to that described in 1.4 of Example 1, except that 5-nitro-1H-imidazole is used instead of imidazole to obtain a white powdery solid with a yield of 40.28%.
[0160] ESI-HRMS(m / z):382.1164[M+Na] + .
[0161] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.44 (s, 1H), 7.96 (s, 2H), 7.91 (d, J = 9.8Hz, 3H), 7.56 (dd, J = 8.4, 1.7Hz, 1H), 7.52(s, 2H), 7.35(s, 2H), 7.07(d, J=8.7Hz, 2H), 5.27(s, 2H), 5.21(s, 2H).
[0162] [Example 9] N-(4-(naphthalen-2-ylmethoxy)benzyl)pyridin-3-amine
[0163]
[0164] The synthesis method was similar to that described in 1.4 of Example 1, except that pyridine-3-amine was used instead of imidazole to obtain the desired product as a white powdery solid with a yield of 32.55%.
[0165] ESI-HRMS (m / z): 341.1648 [M+H] + .
[0166] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.98-7.90 (m, 5H), 7.73 (dd, J=4.7, 1.3Hz, 1H), 7.57 (dd, J=8.4, 1.7Hz, 1H), 7.54-7.50 (m, 2H), 7.29 (d, J=8. 4Hz, 2H), 7.05-7.00 (m, 3H), 6.89 (dt, J=8.7, 2.0Hz, 1H), 6.43 (t, J=6.0Hz, 1H), 5.25 (s, 2H), 4.20 (d, J=5.9Hz, 2H).
[0167] [Example 10] 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0168]
[0169] The synthesis method is similar to that described in 1.4 of Example 1, except that 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 50.97%.
[0170] ESI-HRMS (m / z): 401.1083 [M+H] + .
[0171] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.15 (s, 2H), 8.09 (s, 1H), 7.75 (d, J = 7.7Hz, 1H), 7.25 (d, J = 7.6Hz, 2 H), 7.16 (s, 1H), 7.07-7.02 (m, 2H), 6.89 (s, 1H), 5.29 (s, 2H), 5.12 (s, 2H).
[0172] [Example 11] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0173]
[0174] The synthesis method is similar to that described in 1.4 of Example 1, except that 1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 36.97%.
[0175] ESI-HRMS (m / z): 333.1209 [M+H] + .
[0176] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.78-7.72(m, 3H), 7.65(d, J=8.0Hz, 2H), 7.26-7.21(m, 2H), 7.17( d, J=1.4Hz, 1H), 7.02-6.97 (m, 2H), 6.90 (s, 1H), 5.21 (s, 2H), 5.11 (s, 2H).
[0177] [Example 12] 1-(3-methyl-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0178]
[0179] The synthesis method is similar to that described in Example 1, except that 4-hydroxy-3-methylbenzaldehyde is used instead of 4-hydroxybenzaldehyde to obtain a white powdery solid with a yield of 33.56%.
[0180] ESI-HRMS (m / z): 329.1651 [M+H] +
[0181] 1 H NMR (600 MHz, DMSO-d 6 )δ7.71 (s, 1H), 7.58 (dd, J=8.5, 1.7Hz, 1H), 7.55-7.48 (m, 2H), 7.14 (d, J=1.6Hz, 1H), 7.11 (d, J=2.3Hz, 1H ), 7.07 (dd, J=8.4, 2.3Hz, 1H), 7.03 (d, J=8.4Hz, 1H), 6.87 (s, 1H), 5.27 (s, 2H), 5.06 (s, 2H), 2.21 (s, 3H).
[0182] [Example 13] 1-(3-methoxy-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0183] The synthesis method is similar to that described in Example 1, except that 4-hydroxy-3-methoxybenzaldehyde is used instead of 4-hydroxybenzaldehyde to obtain a white powdery solid with a yield of 34.21%.
[0184]
[0185] ESI-HRMS (m / z): 345.1598 [M+H] + .
[0186] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.96-7.89 (m, 4H), 7.72 (s, 1H), 7.56 (d, J=8.5Hz, 1H), 7.54-7.49 (m, 2H), 7.17 (s, 1H), 7.05 (d, J=8.1H z, 1H), 6.99 (d, J=2.3Hz, 1H), 6.87 (s, 1H), 6.77 (d, J=8.1Hz, 1H), 5.22 (s, 2H), 5.08 (s, 2H), 3.78-3.75 (m, 3H).
[0187] [Example 14] 1-(4-((2,4-di-tert-butylbenzyl)oxy)benzyl)-1H-imidazole
[0188]
[0189] The synthesis method is similar to that described in 1.4 of Example 1, except that 1-(bromomethyl)-3,5-di-tert-butylbenzene is used instead of 2-(bromomethyl)naphthalene to obtain a white powdery solid with a yield of 50.97%.
[0190] ESI-HRMS (m / z): 377.1587 [M+H] + .
[0191] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.15 (s, 2H), 8.09 (s, 1H), 7.75 (d, J = 7.7Hz, 1H), 7.25 (d, J = 7.6Hz, 2 H), 7.16 (s, 1H), 7.07-7.02 (m, 2H), 6.89 (s, 1H), 5.29 (s, 2H), 5.12 (s, 2H).
[0192] [Example 15] 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole
[0193]
[0194] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and pyrazole is used instead of imidazole to obtain a white powdery solid with a yield of 38.84%.
[0195] ESI-HRMS (m / z): 401.1084 [M+H] +
[0196] 1 H NMR (600 MHz, DMSO-d 6)δppm: 8.14 (s, 2H), 8.07 (s, 1H), 7.77 (d, J = 2.2Hz, 1H), 7.43 (d, J = 1.8Hz, 1H), 7.2 4-7.18 (m, 2H), 7.05-7.00 (m, 2H), 6.24 (t, J=2.0Hz, 1H), 5.29 (s, 2H), 5.26 (s, 2H).
[0197] [Example 16] 1-(3-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0198]
[0199] The synthesis method is similar to that described in Example 1, except that 3-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde to obtain a white powdery solid with a yield of 34.21%.
[0200] ESI-HRMS (m / z): 315.1492 [M+H] +
[0201] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.97 (s, 1H), 7.95-7.90 (m, 3H), 7.75 (s, 1H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.55-7.49 (m, 2H), 7.28 (t, J=7. 9Hz, 1H), 7.18 (d, J=1.3Hz, 1H), 7.02-6.96 (m, 2H), 6.89 (s, 1H), 6.83 (d, J=7.5Hz, 1H), 5.25 (s, 2H), 5.16 (s, 2H).
[0202] [Example 17] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole
[0203]
[0204] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and pyrazole is used instead of imidazole to obtain a white powdery solid with a yield of 42.85%.
[0205] ESI-HRMS (m / z): 333.1209 [M+H] + .
[0206] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.79-7.72 (m, 3H), 7.65 (d, J=8.1Hz, 2H), 7.43 (d, J=1.8Hz, 1H), 7.16 (m, 2H), 7.00-6.96 (m, 2H), 6.24 (t, J=2.0Hz, 1H), 5.24 (s, 2H), 5.21 (s, 2H).
[0207] [Example 18] 1-(4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0208]
[0209] The synthesis method is similar to that described in 1.4 of Example 1, except that 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene to obtain the desired product as a white powdery solid with a yield of 39.45%.
[0210] ESI-HRMS (m / z): 351.1115 [M+H] + .
[0211] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.80-7.71(m, 3H), 7.63(dd, J=8.0, 1.8Hz, 1H), 7.27-7.21(m, 2H), 7.15(t, J=1.3Hz, 1H), 7.05-7.00 (m, 2H), 6.88 (d, J=1.2Hz, 1H), 5.76 (s, 1H), 5.23 (s, 2H).
[0212] [Example 19] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-tetrazolyl
[0213]
[0214] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-tetrazole is used instead of imidazole to obtain a white powdery solid with a yield of 46.83%.
[0215] ESI-HRMS(m / z):339.1214[M+Na] + .
[0216] 1 H NMR (600 MHz, DMSO-d 6)δppm: 8.95 (s, 1H), 7.97 (s, 1H), 7.95-7.90 (m, 3H), 7.56 (dd, J=8.4, 1.8Hz, 1H), 7. 53(d, J=5.1Hz, 2H), 7.36-7.31(m, 2H), 7.09-7.05(m, 2H), 5.87(s, 2H), 5.27(s, 2H).
[0217] [Example 20] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-2H-tetrazolyl
[0218] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-tetrazole is used instead of imidazole to obtain a white powdery solid with a yield of 47.74%.
[0219]
[0220] ESI-HRMS(m / z):339.1214[M+Na] + .
[0221] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 9.47 (s, 1H), 7.99-7.89 (m, 4H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.54-7 .50(m,2H),7.36-7.30(m,2H),7.10-7.05(m,2H),5.62(s,2H),5.27(s,2H).
[0222] [Example 21] 1-(2-fluoro-4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0223]
[0224] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 2-fluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde to obtain a white powdery solid with a yield of 26.54%.
[0225] ESI-HRMS (m / z): 351.1115 [M+H] + .
[0226] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.80-7.73 (m, 3H), 7.66 (d, J=8.0Hz, 2H), 7.25-7.17 (m, 3H), 7.05 (d, J=7.6Hz, 1H), 6.89 (s, 1H), 5.29 (s, 2H), 5.11 (s, 2H).
[0227] [Example 22] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0228]
[0229] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 2,3-difluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde to obtain a white powdery solid with a yield of 26.54%.
[0230] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.81-7.75 (m, 2H), 7.72 (s, 1H), 7.66 (dd, J=8.1, 1.8Hz, 1H), 7.19 (td, J=8.2, 1.7 Hz, 1H), 7.15 (s, 1H), 7.09 (td, J=8.3, 2.1Hz, 1H), 6.90 (s, 1H), 5.36 (s, 2H), 5.24 (s, 2H).
[0231] 13 C NMR (151 MHz, DMSO-d 6 )δ161.24, 159.58, 149.50, 147.88, 146.44, 141.54, 139.92, 131.79, 128.66, 1 24.64, 124.11, 123.59, 122.82, 122.07, 113.59, 113.43, 110.78, 65.09, 56.89.
[0232] [Example 23] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0233]
[0234] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white powdery solid with a yield of 27.65%.
[0235] ESI-HRMS (m / z): 373.1547 [M+H]+ .
[0236] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.98-7.88 (m, 5H), 7.86 (d, J=1.2Hz, 1H), 7.56 (dd, J=8.4, 1.6Hz, 1H), 7.54-7.5 0(m, 2H), 7.33-7.28(m, 2H), 7.08-7.03(m, 2H), 5.26(s, 2H), 5.15(s, 2H), 3.71(s, 3H).
[0237] [Example 24] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0238]
[0239] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white powdery solid with a yield of 25.63%.
[0240] ESI-HRMS (m / z): 373.1547 [M+H] + .
[0241] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.13 (s, 1H), 7.98-7.89 (m, 4H), 7.67 (s, 1H), 7.56 (dd, J=8.4, 1.6Hz, 1H), 7.54-7. 50(m,2H),7.19-7.14(m,2H),7.05-6.99(m,2H),5.44(s,2H),5.24(s,2H),3.74(s,3H)..
[0242] [Example 25] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester
[0243]
[0244] The synthesis method is similar to that described in 1.4 of Example 1, except that 1H-pyrazole-4-carboxylic acid ethyl ester is used instead of 1H-imidazole to obtain a white solid with a yield of 82.09%.
[0245] ESI-HRMS (m / z): 387.1711 [M+H] + .
[0246] 1H NMR (600 MHz, DMSO-d 6 )δppm: 8.40 (s, 1H), 7.99-7.89 (m, 4H), 7.84 (s, 1H), 7.59-7.49 (m, 3H), 7.25 (d, J=2.4Hz, 2H) , 7.07-7.01 (m, 2H), 5.27 (s, 2H), 5.26 (s, 2H), 4.19 (d, J = 21.3Hz, 2H), 1.25 (t, J = 7.1Hz, 3H).
[0247] [Example 26] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid
[0248]
[0249] 1-(4-(naphthalene-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester (0.15 g, 0.41 mmol), water and lithium hydroxide (0.068 g, 1.61 mmol) were dissolved in a mixed solution of tetrahydrofuran (20 mL) and water (20 mL) in sequence, heated to 40°C and stirred for one hour. After the reaction was completed by TLC monitoring, the tetrahydrofuran was removed by vacuum concentration, and the product precipitated, filtered and the filter cake was washed with dichloroethane (20 mL×3) to obtain 0.12 g of a white powdery solid, with a yield of 80.83%.
[0250] ESI-HRMS (m / z): 359.1391 [M+H] + .
[0251] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 12.79 (s, 1H), 8.06 (s, 1H), 8.00-7.88 (m, 4H), 7.63-7.47 (m, 4H), 7.16 (d, J=8.7Hz, 2H), 7.08-6.97 (m, 2H), 5.44 (s, 2H), 5.24 (s, 2H).
[0252] [Example 27] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid
[0253]
[0254] The synthesis method is similar to that described in Example 26, except that 1-(4-(naphthalene-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester is used to replace 1-(4-(naphthalene-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester to obtain a white powdery solid with a yield of 84.86%.
[0255] ESI-HRMS (m / z): 359.1392 [M+H] + .
[0256] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.01-7.88 (m, 4H), 7.67 (s, 1H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.54-7.5 0(m, 2H), 7.31-7.21(m, 3H), 7.05(d, J=8.3Hz, 2H), 5.26(s, 2H), 5.07(s, 2H)..
[0257] [Example 28] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0258]
[0259] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, 2,3-difluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid with a yield of 29.76%.
[0260] ESI-HRMS (m / z): 445.0981 [M+H] + .
[0261] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.09 (s, 1H), 7.81-7.73 (m, 2H), 7.71 (s, 1H), 7.65 (d, J=8.0Hz, 1H), 7.13 (d, J=7.3Hz, 1H), 6.75 (t, J=8.4Hz, 1H), 5.56 (s, 2H), 5.33 (s, 2H), 3.73 (s, 3H)..
[0262] [Example 29] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0263]
[0264] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, 2,3-difluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid with a yield of 25.43%.
[0265] ESI-HRMS (m / z): 445.0981 [M+H] +
[0266] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.90 (s, 1H), 7.85 (s, 1H), 7.81-7.75 (m, 2H), 7.66 (d, J=8.0Hz, 1H), 7.18 (dd, J=14.7, 7.8Hz, 2H), 5.36 (s, 2H), 5.30 (s, 2H), 3.72 (s, 3H).
[0267] [Example 30] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid
[0268] The synthesis method is similar to that described in Example 26, except that 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester is used instead of 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester to obtain a white powdery solid with a yield of 76.52%.
[0269]
[0270] ESI-HRMS (m / z): 431.0825 [M+H] +
[0271] 1 H NMR (600MHz, DMSO) δ12.92 (s, 1H), 7.95 (s, 1H), 7.81-7.75 (m, 2H), 7.66 (d, J=7.9, 1.7H z, 1H), 7.57 (s, 1H), 7.12 (t, J=8.2Hz, 1H), 6.76-6.70 (m, 1H), 5.58 (s, 2H), 5.33 (s, 2H).
[0272] [Example 31] 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid
[0273]
[0274] The synthesis method is similar to that described in Example 26, except that 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester is used instead of 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester to obtain a white powdery solid with a yield of 75.65%.
[0275] ESI-HRMS (m / z): 431.0825 [M+H] +
[0276] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 12.22 (s, 1H), 7.86-7.71 (m, 4H), 7.66 (d, J=8.0Hz, 1H), 7.19 (dq, J=16.5, 8.4Hz, 2H), 5.36 (s, 2H), 5.29 (s, 2H).
[0277] [Example 32] 1-(3-fluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0278]
[0279] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, 3-fluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 27.98%
[0280] ESI-HRMS (m / z): 427.1077 [M+H] +
[0281] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.98 (d, J=1.3Hz, 1H), 7.89 (d, J=1.3Hz, 1H), 7.79-7.74 (m, 2H), 7.65 (dd, J=8.0, 1.8H z, 1H), 7.34-7.28 (m, 2H), 7.15 (dt, J=8.3, 1.5Hz, 1H), 5.31 (s, 2H), 5.17 (s, 2H), 3.72 (s, 3H).
[0282] [Example 33] 3-(4-((3-fluoro-5-(trifluoromethyl)benzyl)oxy)benzyl)-4H-4-imidazole-5-carboxylic acid methyl ester
[0283]
[0284] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-3-fluoro-5-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, 3-fluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 27.98%
[0285] ESI-HRMS (m / z): 427.1076 [M+H] +
[0286] 1 H NMR (600 MHz, DMSO-d 6 )δppm 8.07 (d, J=1.8Hz, 1H), 7.94 (d, J=1.3Hz, 1H), 7.87 (d, J=1.3Hz, 1H), 7.81 (dd, J=8.1, 1.8Hz, 1H), 7 .76(d, J=8.1Hz, 1H), 7.34-7.31(m, 2H), 7.05-7.02(m, 2H), 5.20(s, 2H), 5.17(s, 2H), 3.71(s, 3H).
[0287] [Example 34] 1-(3-fluoro-4-(perfluorophenyl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0288]
[0289] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-2,3,4,5,6-pentafluorobenzene is used instead of 2-(bromomethyl)naphthalene, 3-fluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 27.49%
[0290] ESI-HRMS (m / z): 431.0825 [M+H] +
[0291] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.14-8.08 (m, 2H), 7.94 (d, J = 1.3Hz, 1H), 7.88 (d, J = 1.3Hz, 1H), 7.70-7.64 ( m, 3H), 7.36-7.31 (m, 3H), 7.12-7.08 (m, 2H), 5.50 (s, 2H), 5.17 (s, 2H), 3.72 (s, 3H).
[0292] [Example 35] 1-(3-fluoro-4-((3-fluoro-3-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0293] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-3-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, 3-fluoro-4-hydroxybenzaldehyde is used instead of 4-hydroxybenzaldehyde, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 29.78%
[0294]
[0295] ESI-HRMS (m / z): 427.1075 [M+H] +
[0296] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.97 (d, J=1.3Hz, 1H), 7.88 (d, J=1.3Hz, 1H), 7.83 (t, J=7.8Hz, 1H), 7.56 (d, J=11.6Hz, 1H), 7.47 (d, J=8.1Hz, 1 H), 7.33 (dd, J=12.0, 2.1Hz, 1H), 7.22 (t, J=8.6Hz, 1H), 7.14 (d, J=8.3Hz, 1H), 5.30 (s, 2H), 5.16 (s, 2H), 3.71 (s, 3H).
[0297] [Example 36] 1-(4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0298]
[0299] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-3-fluoro-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 29.78%
[0300] ESI-HRMS (m / z): 409.1171 [M+H] + .
[0301] 1H NMR (600 MHz, DMSO-d 6)δppm: 7.93 (d, J=1.0Hz, 1H), 7.86 (d, J=1.1Hz, 1H), 7.81 (t, J=7.8Hz, 1H), 7.56 (d, J=11.7Hz, 1H), 7.46 (d, J=8.1Hz, 1H), 7.31 (d, J=8.7Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 5.22 (s, 2H), 5.16 (s, 2H), 3.71 (s, 3H)..
[0302] [Example 37] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0303]
[0304] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid. Yield: 25.38%
[0305] ESI-HRMS (m / z): 391.1264 [M+H] +
[0306] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.13 (s, 1H), 7.74 (d, J=8.1Hz, 2H), 7.69-7.62 (m, 3H), 7.19-7.14 (m, 2H), 7.01-6.96 (m, 2H), 5.44 (s, 2H), 5.19 (s, 2H), 3.74 (s, 3H).
[0307] [Example 38] 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0308] The synthesis method is similar to that described in Example 1, except that 1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid with a yield of 22.87%.
[0309]
[0310] ESI-HRMS (m / z): 391.1263 [M+H] +
[0311] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.93 (d, J=1.3Hz, 1H), 7.86 (d, J=1.4Hz, 1H), 7.75 (d, J=8.0Hz, 2H), 7.65 (d, J=8 .0Hz, 2H), 7.33-7.26(m, 2H), 7.04-7.00(m, 2H), 5.21(s, 2H), 5.15(s, 2H), 3.71(s, 3H).
[0312] [Example 39] 1-(4-((2-bromo-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0313]
[0314] The synthesis method is similar to that described in Example 1, except that 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene is used instead of 2-(bromomethyl)naphthalene, and 1H-imidazole-4-carboxylic acid methyl ester is used instead of imidazole to obtain a white solid with a yield of 27.43%.
[0315] ESI-HRMS (m / z): 469.0369 [M+H] +
[0316] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.07 (s, 1H), 7.94 (d, J = 1.3Hz, 1H), 7.87 (d, J = 1.3Hz, 1H), 7.82 (d, J = 8.1Hz, 1H), 7.77 ( d, J=8.0Hz, 1H), 7.35-7.30(m, 2H), 7.07-7.01(m, 2H), 5.20(s, 2H), 5.17(s, 2H), 3.71(s, 3H).
[0317] [Example 40] The synthesis method of 1-(4-((4-fluoronaphthalen-1-yl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester is similar to that described in Example 1, using 1-(bromomethyl)-4-fluoronaphthalene instead of 2-(bromomethyl)naphthalene, and 1H-imidazole-4-carboxylic acid methyl ester instead of imidazole to obtain a white solid with a yield of 28.10%.
[0318]
[0319] ESI-HRMS (m / z): 391.1452 [M+H] +
[0320] 1 H NMR (600 MHz, DMSO-d 6)δppm: 8.14-8.08 (m, 2H), 7.94 (d, J=1.3Hz, 1H), 7.88 (d, J=1.3Hz, 1H), 7.70-7.64 (m, 3H ), 7.34 (dd, J=9.9, 7.7Hz, 3H), 7.12-7.08 (m, 2H), 5.50 (s, 2H), 5.17 (s, 2H), 3.72 (s, 3H).
[0321] [Example 41] 1-(4-(cyclohexylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0322]
[0323] The synthesis method was similar to that described in Example 1, except that (bromomethyl)cyclohexane was used instead of 2-(bromomethyl)naphthalene and 1H-imidazole-4-carboxylic acid methyl ester was used instead of imidazole to obtain a white solid with a yield of 31.07%.
[0324] ESI-HRMS (m / z): 329.1861 [M+H] +
[0325] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.91 (s, 1H), 7.85 (s, 1H), 7.27 (d, J = 8.7Hz, 2H), 6.90 (d, J = 8.6Hz, 2H), 5.14 (s, 2H), 3.75 (d, J = 6.5Hz, 2H), 3.71 (s, 3H), 1. 77 (d, J=12.4Hz, 2H), 1.72-1.61 (m, 4H), 1.24 (td, J=10.5, 9.5, 4.1Hz, 3H), 1.17 (ddt, J=24.9, 12.5, 3.3Hz, 2H), 1.06-0.96 (m, 2H).
[0326] [Example 42] N 1 -(4-(Naphthalen-2-ylmethoxy)benzyl)ethane-1,2-diamine
[0327] 42.1 [Preparation of intermediate] tert-butyl (2-((4-(naphthalen-2-ylmethoxy)benzyl)amino)ethyl)carbamate
[0328]
[0329] Under ice bath condition (0 ℃), NaH (44.00mg, 1.83mmol) was added to DMF solution (15mL) dissolved with tert-butyl (2-aminoethyl) carbamate (217.43mg, 1.36mmol) and stirred for 30min under ice bath condition. Then 2-((4-(bromomethyl)phenoxy)methyl)naphthalene (400.01mg, 1.22mmol) was added to the stirred solution. The reaction mixture was slowly warmed to room temperature and then stirred at 60 ℃ for 4 hours. After the reaction was completed by TLC monitoring, the mixture was cooled to room temperature and slowly poured into saturated NH 4 The mixture was quenched with aqueous Cl solution (45 mL) and then washed with CH 2 Cl 2 Extract (20 mL × 3) and wash with saturated brine (40 mL × 3), combine the organic phases and add anhydrous MgSO 4 Dry, filter and concentrate in vacuo to remove CH 2 Cl 2 The obtained residue was purified by silica gel column chromatography (0% to 10% MeOH / CH 2 Cl 2 ) to obtain the intermediate tert-butyl (2-((4-(naphthalen-2-ylmethoxy)benzyl)amino)ethyl)carbamate as a light yellow solid, 0.35 g, yield: 64.29%.
[0330] ESI-HRMS (m / z): 407.23 [M+H] + .
[0331] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.98 (s, 1H), 7.96-7.90 (m, 3H), 7.58 (dd, J=8.4, 1.8Hz, 1H), 7.53 (td, J=5.9, 5.5, 3.1Hz, 2H), 7.44 (d, J=8.0Hz, 2H), 7. 12 (d, J=8.2Hz, 2H), 7.01 (t, J=5.8Hz, 1H), 5.31 (s, 2H), 4.06 (s, 2H), 3.24 (q, J=6.5Hz, 2H), 2.91 (t, J=6.6Hz, 2H), 1.38 (s, 9H).
[0332] 42.2 [Preparation of Example 42] N 1 -(4-(Naphthalen-2-ylmethoxy)benzyl)ethane-1,2-diamine
[0333]
[0334] To a stirred solution of tert-butyl (2-((4-(naphthalen-2-ylmethoxy)benzyl)amino)ethyl)carbamate (200 mg, 0.49 mmol) in EtOH (10 mL) was added C 2 H 5 OH·HCl (1 mL, 1 M). The mixture was refluxed for 3 h, concentrated in vacuo, filtered and dried. The filtrate was poured into DCM (20 mL) and washed with saturated aqueous sodium bicarbonate solution, anhydrous MgSO 4 Dry, filter and concentrate to obtain a powdery white solid, yield: 19.75%
[0335] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 9.01 (s, 2H), 7.99 (s, 1H), 7.97-7.90 (m, 3H), 7.58 (dd, J=8.5, 1.7Hz, 1H), 7.56- 7.47(m, 4H), 7.13(d, J=8.7Hz, 2H), 5.29(s, 2H), 4.49(s, 2H), 4.33(s, 2H), 4.16(s, 3H).
[0336] 13 C NMR (151 MHz, DMSO-d 6 )δ159.59, 134.89, 133.23, 133.05, 132.16, 128.58, 128.27, 128.09, 126.89, 126.83, 126.66, 126.24, 122.97, 115.67, 69.90, 56.54, 55.75.
[0337] [Example 43] N-(4-(naphthalen-2-ylmethoxy)benzyl)piperidin-4-amine
[0338]
[0339] The synthesis method is similar to that of Example 42, except that tert-butyl 4-aminopiperidincarboxylate is used instead of tert-butyl (2-aminoethyl)carbamate to obtain the desired product as a white solid. Yield: 38.21%.
[0340] ESI-HRMS (m / z): 347.2115 [M+H] + .
[0341] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.99 (d, J=1.6Hz, 1H), 7.96-7.90 (m, 3H), 7.58 (dd, J=8.4, 1.7Hz, 1H), 7.56-7.49 (m, 4H), 7.14-7.09 (m, 2H), 5.32 (s, 2H), 4.08 (t, J=5.9Hz, 2H), 3.37 (m, 2H), 3.27 (dt, J=11.4, 5.9Hz, 1H), 2.94-2.86 (m, 2H), 2.24 (d, J=13.2Hz, 2H), 1.89 (qd, J=13.2, 4.1Hz, 2H).
[0342] [Example 44] 1-(4-(naphthalene-2-ylmethoxy)benzyl)azetidine-3-amine
[0343]
[0344] The synthesis method was similar to that of Example 42, except that tert-butyl azetidin-3-ylcarbamate was used instead of tert-butyl (2-aminoethyl)carbamate to obtain the desired product as a white solid. Yield: 40.21%.
[0345] ESI-HRMS (M / Z): 319.1805 [M+H] +
[0346] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.90 (s, 2H), 7.95 (d, J=43.6Hz, 4H), 7.51 (d, J=25.9Hz, 5H), 7.14 (s, 2H), 5.30 (s, 2H), 4.52-4.00 (m, 7H).
[0347] [Example 45] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid butyl ester
[0348]
[0349] 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester (238.32 mg, 0.64 mmol) was dissolved in excess n-butanol (600.10 mg, 1.62 mmol), potassium carbonate (444.66 mg, 3.21 mmol) was added, heated and stirred at 40°C, and the mixture was purified by silica gel chromatography (0%-10% MeOH / CH 2 Cl 2 ) was purified to give a white solid, 236.43 mg, yield: 89.13%.
[0350] ESI-HRMS (m / z): 415.2017 [M+H] +
[0351] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.00-7.89 (m, 5H), 7.85 (d, J=15.5Hz, 1H), 7.56 (d, J=8.4Hz, 1H), 7.52 (dt, J=5.4, 2.7Hz, 2H), 7.30 (d, J=8.8Hz, 2H), 7.06 (d, J =8.5Hz, 2H), 5.26 (s, 2H), 5.16 (s, 2H), 4.18-4.10 (m, 2H), 1.60 (t, J = 7.7Hz, 2H), 1.36 (dt, J = 15.0, 7.4Hz, 2H), 0.89 (t, J = 7.5Hz, 3H).
[0352] [Example 46] 2-(2-methoxyethoxy)ethoxyethyl-1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylate
[0353]
[0354] The synthesis method is similar to that described in Example 45, except that triethylene glycol is used instead of n-butanol to obtain a transparent oily liquid with a yield of 61.43%.
[0355] ESI-HRMS(m / z):491.2177[M-C+H] + .
[0356] 1 H NMR (600 MHz, CDCl 3 )8ppm: 7.89-7.82 (m, 4H), 7.62 (s, 1H), 7.56 (s, 1H), 7.53 (dd, J=8.3, 1.8Hz, 1H), 7.49 (td, J=5.7, 3.1Hz, 2H), 7.17-7.12 (m, 2H), 7.04-6.99 (m, 2H), 5.23 (s, 2H), 5.05 (s, 2H), 4.44 (t, J=4.8Hz, 2H), 4.26-4.21 (m, 2H), 3.80 (t, J=4.9Hz, 4H), 3.72-3.69 (m, 4H), 3.59 (t, J=4.6Hz, 3H).
[0357] [Example 47] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid hexan-2-yl ester
[0358]
[0359] The synthesis method is similar to that described in Example 45, except that 2-hexanol is used instead of n-butanol to obtain a white solid with a yield of 83.58%.
[0360] ESI-HRMS (m / z): 443.2330 [M+H] +
[0361] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.98-7.89 (m, 4H), 7.86 (d, J=9.3Hz, 2H), 7.56 (d, J=8.5Hz, 1H), 7.52 (p, J=5.3Hz, 2H), 7.31 (d, J=8.3Hz, 2H), 7.06 (d, J=8.3Hz, 2 H), 5.26 (s, 2H), 5.15 (s, 2H), 4.94 (h, J=6.3Hz, 1H), 1.63-1.48 (m, 2H), 1.31-1.23 (m, 4H), 1.20 (d, J=6.2Hz, 3H), 0.84 (t, J=6.6Hz, 3H).
[0362] [Example 48] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid isopropyl ester
[0363]
[0364] The synthesis method is similar to that described in Example 45, except that n-butanol is replaced by isopropanol, potassium carbonate is replaced by cesium carbonate, and the heating temperature is changed to 70°C to obtain a white powdery solid with a yield of 77.43%.
[0365] ESI-HRMS(m / z):401.1865[M+H] + .
[0366] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.97 (s, 1H), 7.92 (t, J=9.4Hz, 3H), 7.85 (d, J=5.7Hz, 2H), 7.56 (d, J=8.4Hz, 1H), 7.54-7.50 (m, 2H), 7.30 (d , J=8.6Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 5.26 (s, 2H), 5.15 (s, 2H), 5.03 (hept, J=6.2Hz, 1H), 1.23 (d, J=6.2Hz, 6H)..
[0367] [Example 49] 1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid propyl ester
[0368]
[0369] The synthesis method is similar to that described in Example 45, except that n-butanol is replaced with 1-propanol and the heating temperature is changed to 45°C to obtain a white powdery solid with a yield of 70.56%.
[0370] ESI-HRMS (m / z): 401.1859 [M+H] +
[0371] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.96 (d, J=7.0Hz, 1H), 7.95-7.89 (m, 4H), 7.86 (s, 1H), 7.56 (dd, J=8.4, 1.7Hz, 1H), 7.52 (q, J=4.3Hz, 2H), 7.33-7.2 8 (m, 2H), 7.08-7.03 (m, 2H), 5.26 (s, 2H), 5.15 (s, 2H), 4.10 (t, J=6.7Hz, 2H), 1.64 (h, J=7.2Hz, 2H), 0.91 (t, J=7.4Hz, 3H).
[0372] [Example 50] 1-(4-((naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole
[0373] 50.1 [Preparation of intermediate] Methyl 4-(naphthalen-2-ylmethyl)thio)benzoate
[0374]
[0375] The synthesis method is similar to the method described in 1.1 of Compound Example 1, except that 4-hydroxybenzaldehyde is replaced by methyl 4-mercaptobenzoate to obtain a light yellow solid with a yield of 93.22%, which is directly used in the next step without purification.
[0376] 50.2 [Preparation of intermediate] (4-((naphthalen-2-ylmethyl)thio)phenyl)methanol
[0377]
[0378] Methyl 4-(naphthalene-2-ylmethyl)thio)benzoate (0.13 g, 0.41 mmol) and lithium hydroxide monohydrate (0.068 g, 1.61 mmol) were dissolved in a mixed solution of tetrahydrofuran (20 mL) and water (20 mL) in sequence, heated to 40°C and stirred for one hour. After the reaction was completed by TLC monitoring, the tetrahydrofuran was removed by vacuum concentration, and the product precipitated. The filter cake was filtered and washed with dichloroethane (20 mL×3) to obtain the desired product as a white powdery solid (0.12 g), with a yield of 78.02%, which was directly used for the next step without purification.
[0379] 50.4 [Preparation of Example 50] 1-(4-((naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole
[0380]
[0381] The synthesis method is similar to that described in 1.4 of Example 1, except that (4-(bromomethyl)phenyl)(naphthalen-2-ylmethyl)sulfane is used instead of 1-(bromomethyl)-2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzene, and the mixture is purified by column chromatography (0% to 7% MeOH / CH 2 Cl 2 ) to obtain the target compound as a white solid. Yield: 33.11%.
[0382] ESI-HRMS (m / z): 331.1263 [M+H] +
[0383] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.86 (t, J=8.6Hz, 2H), 7.81 (d, J=9.0Hz, 2H), 7.71 (s, 1H), 7.52 (dd, J=8.4, 1.8Hz, 1H), 7.48 (q d, J=7.2, 3.5Hz, 2H), 7.34 (d, J=8.3Hz, 2H), 7.17-7.12 (m, 3H), 6.88 (s, 1H), 5.12 (s, 2H), 4.40 (s, 2H).
[0384] [Example 51] 1-(4-((naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-5-carboxylic acid methyl ester
[0385]
[0386] The synthesis method is similar to the method described in 1.4 of Example 1, except that (4-(bromomethyl)phenyl)(naphthalen-2-ylmethyl)sulfane is used instead of 2-((4-(bromomethyl)phenoxy)methyl)naphthalene. The product is purified by column chromatography (0% to 70% PE / EA) to obtain a white solid with a yield of 31.21%.
[0387] ESI-HRMS (m / z): 389.1317 [M+H] +
[0388] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 8.12 (d, J=1.1Hz, 1H), 7.85 (dd, J=11.5, 7.7Hz, 2H), 7.83-7.78 (m, 2H), 7.68 (d, J=1.1Hz, 1H ), 7.53-7.44(m, 3H), 7.35-7.29(m, 2H), 7.10-7.04(m, 2H), 5.45(s, 2H), 4.38(s, 2H), 3.71(s, 3H).
[0389] [Example 52] 1-(4-((naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid methyl ester
[0390]
[0391] The synthesis method is similar to the method described in 1.4 of Example 1, except that (4-(bromomethyl)phenyl)(naphthalen-2-ylmethyl)sulfane is used instead of 2-((4-(bromomethyl)phenoxy)methyl)naphthalene. The product is purified by column chromatography (0% to 70% PE / EA) to obtain a white solid with a yield of 30.65%.
[0392] ESI-HRMS (m / z): 389.1318 [M+H] +
[0393] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.93 (d, J=1.3Hz, 1H), 7.89-7.82 (m, 3H), 7.80 (d, J=9.3Hz, 2H), 7.51 (dd, J=8.5, 1.8Hz, 1H ), 7.50-7.45(m, 2H), 7.38-7.33(m, 2H), 7.26-7.20(m, 2H), 5.17(s, 2H), 4.40(s, 2H), 3.71(s, 3H).
[0394] [Example 53] 1-(4-((naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid butyl ester
[0395]
[0396] The synthesis method is similar to that described in Example 45, except that 1-(4-(naphthalene-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester is replaced with 1-(4-((naphthalene-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid methyl ester to give a white powdery solid with a yield of 75.08%.
[0397] ESI-HRMS (m / z): 431.1789 [M+H] +
[0398] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 7.90 (d, J=1.3Hz, 1H), 7.88-7.83 (m, 3H), 7.80 (d, J=9.7Hz, 2H), 7.51 (d, J=8.3Hz, 1H), 7.48 (tt, J=6.6, 3.6Hz, 2H), 7.35 (d, J=8.1Hz, 2H), 7.23 (d, J=8.1Hz, 2H), 5.17 (s, 2H), 4.40 (s, 2H), 4.14 (t, J=6.6Hz, 2H), 1 .60 (dt, J=14.6, 6.7Hz, 2H), 1.36 (q, J=7.5Hz, 2H), 0.90 (t, J=7.4Hz, 3H).
[0399] [Example 54] 1-(4-((6-bromonaphthalen-2-yl)methoxy)benzyl)-1H-imidazole
[0400] 54.1
Preparation of intermediates
[0401] Under ice bath conditions (0°C), methyl 6-bromo-2-naphthoate (8.00 g, 30.18 mmol) was dissolved in anhydrous THF (80 mL), and then LiAlH 4 The mixture was stirred in an ice bath for 30 minutes with tetrahydrofuran solution (1M, 36mL). After the reaction was completed by TLC monitoring, the reaction solution was slowly poured into 0.5M dilute hydrochloric acid (100mL) in an ice bath, the internal temperature was kept below 5°C, the precipitate was filtered and washed with water, and vacuum dried to obtain the intermediate 6-bromo-2-naphthalene-methanol as a light yellow powdery solid 6.79g, yield: 95.32%, which was directly put into the next step without purification.
[0402] 54.2 [Preparation of intermediates] 4-((6-bromonaphthalen-2-yl)methoxy)benzaldehyde
[0403] 6-bromo-2-naphthalene-methanol (4.01 g, 16.90 mmol), 4-hydroxybenzaldehyde (1.79 g, 14.09 mmol), and triphenylphosphine (4.45 g, 16.90 mmol) were added to anhydrous THF (50 mL) solution in sequence, and diisopropyl azodicarboxylate (3.43 g, 16.90 mmol) was added dropwise under nitrogen protection and stirred at room temperature for 1 hour. After the reaction was completed by TLC monitoring, most of the THF was removed by vacuum rotary evaporation, water (100 mL) was added, and CH 2 Cl 2 Extract three times (50 mL × 3), combine the organic phases and wash with anhydrous MgSO 4 Dry, filter and concentrate in vacuo. The residue is purified by silica gel column chromatography (0% to 10% EA / PE) to obtain 3.55 g of a light yellow powdery solid. Yield: 61.23%.
[0404] 54.3 [Preparation of Example 54] 1-(4-((6-bromonaphthalen-2-yl)methoxy)benzyl)-1H-imidazole
[0405]
[0406] The synthesis method is similar to that of Example 1. The above intermediate is reduced and brominated to obtain 2-bromo-6-((4-(bromomethyl)phenoxy)methyl)naphthalene (0.30 g, 0.74 mmol), imidazole (75.57 mg, 1.11 mmol) and K 2 CO 3 (0.20 g, 1.48 mmol) were added to acetonitrile (20 mL) in sequence, and the temperature was raised to 60°C and stirred for 3 hours. After the reaction was completed by TLC monitoring, most of the acetonitrile was removed by vacuum rotary evaporation, and the mixture was washed with water and then precipitated with CH 2 Cl 2 Extraction (45 mL × 3), the organic phases were combined and MgSO 4 The residue was purified by silica gel column chromatography (0% to 10% MeOH / CH 2 Cl 2 ) The target product was obtained as a white solid, 87.25 mg, yield: 30.01%.
[0407] ESI-HRMS (m / z): 393.0596 [M+H] + .
[0408] 1 H NMR (600 MHz, DMSO-d 6)δppm: 8.21 (s, 1H), 8.00 (s, 1H), 7.92 (dd, J=18.1, 8.6Hz, 2H), 7.71 (s, 1H), 7.63 (ddd, J=15.1, 8.6, 1. 9Hz, 2H), 7.23 (d, J=8.7Hz, 2H), 7.14 (s, 1H), 7.06-7.01 (m, 2H), 6.87 (s, 1H), 5.25 (s, 2H), 5.10 (s, 2H).
[0409] [Example 55] 1-(4-((6-ethylnaphth-2-yl)methoxy)benzyl)-1H-imidazole
[0410]
[0411] 1-(4-((6-bromonaphthalen-2-yl)methoxy)benzyl)-1H-imidazole (0.026 g, 0.66 mmol), ethylboronic acid (0.082 g, 1.11 mmol) and K 2 CO 3 (0.20 g, 1.48 mmol) was dissolved in 1,4-dioxane (20 mL), heated to 115°C and stirred for 24 hours. After the reaction was completed, the mixture was filtered through celite, water (50 mL) was added and the mixture was washed with CH 2 Cl 2 (50 mL × 3) extraction, the organic phases were combined and washed with anhydrous MgSO 4 The residue was purified by silica gel column chromatography (0% to 10% MeOH / CH 2 Cl 2 ) was purified to give a white solid, 87.25 mg, yield: 38.54%.
[0412] ESI-HRMS (m / z): 343.1805 [M+H] + .
[0413] 1 H NMR (600 MHz, DMSO-d 6)δppm: 7.91 (d, J=9.5Hz, 1H), 7.84 (dd, J=10.4, 8.5Hz, 2H), 7.72 (d, J=27.9Hz, 2H), 7.53-7.50 (m, 1H), 7.41 (dd, J=8.3, 1.7Hz, 1H), 7.23 (d d, J=8.9, 2.5Hz, 2H), 7.16 (s, 1H), 7.06-7.00 (m, 2H), 6.88 (s, 1H), 5.23 (s, 2H), 5.10 (s, 2H), 2.77 (q, J=7.6Hz, 2H), 1.27 (t, J=7.6Hz, 3H).
[0414] Example 56 (1H-imidazol-4-yl)(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)methanol
[0415]
[0416] 4-iodo-1-tributyl-1H-imidazole (0.22 g, 0.50 mmol) was dissolved in anhydrous THF (30 mL), and an ether solution of EtMgBr (3 M, 0.33 mL) was slowly added dropwise under nitrogen protection. After 1.5 hours of reaction, 4-(trifluoromethyl)benzaldehyde (0.16 g, 0.61 mmol) was added and stirred overnight. After the reaction was completed by TLC monitoring, a few drops of methanol were carefully added to quench the reaction. The crude product was directly used in the next step without further purification.
[0417] Add acetic acid (1 mL) to the mixed solution in the previous step and stir the solution at 80°C for 2 hours. Cool the reaction mixture to room temperature and adjust the pH to 9-10 with 10% NaOH aqueous solution. Extract the aqueous phase with ethyl acetate (20 mL x 3). Wash with water and brine and combine the organic layers and dry. Concentrate in vacuo to remove the solvent to obtain 66.42 mg of a pale yellow solid crude product with a yield of 40.21%.
[0418] ESI-HRMS(m / z):331.1052[M-OH+H] + .
[0419] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 11.99 (s, 1H), 7.76 (d, J=8.2Hz, 2H), 7.66 (d, J=8.1Hz, 2H), 7.55 (s, 1H), 7. 30 (d, J=8.7Hz, 2H), 6.97 (d, J=8.6Hz, 2H), 6.81 (s, 1H), 5.21 (s, 2H), 5.19 (s, 1H).
[0420] [Example 57] 4-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole
[0421]
[0422] (1H-imidazole-4-yl)(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)methanol was dissolved in 1,2-difluoroethane (20 mL). Trifluoroacetic acid (1 mL) was added under nitrogen protection and the mixture was heated to 80°C and stirred. After the reaction was completed as monitored by TLC, the reaction solution was poured into a saturated sodium bicarbonate solution (40 mL) and quenched until no bubbles were generated. The organic phase was separated and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated to obtain a white powdery solid. The yield was 25.63%.
[0423] ESI-HRMS (m / z): 333.1209 [M+H] + .
[0424] 1 H NMR (600 MHz, DMSO-d 6 )δppm: 12.06 (s, 1H), 7.75 (d, J=8.2Hz, 2H), 7.65 (d, J=8.1Hz, 2H), 7.59 (s, 1H), 7. 14 (d, J=8.5Hz, 2H), 6.92 (d, J=8.6Hz, 2H), 6.72 (s, 1H), 5.19 (s, 2H), 3.77 (s, 2H).
[0425] [Example 58] 4-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole
[0426]
[0427] The synthesis method is similar to that described in Example 57, except that (1H-imidazol-4-yl)(4-(naphthalen-2-ylmethoxy)phenyl)methanol is used instead of (1H-imidazol-4-yl)(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)methanol to give a white solid with a yield of 12.23%.
[0428] ESI-HRMS (m / z): 315.1492 [M+H] + .
[0429] 1 H NMR (600 MHz, DMSO-d 6)δppm: 12.22 (s, 1H), 7.96 (s, 1H), 7.95-7.89 (m, 3H), 7.67 (s, 1H), 7.56 (dd, J=8.3, 1.7Hz, 1H), 7.51 (q, J=5.6, 4.8Hz, 2H), 7.14 (d, J=8.4Hz, 2H), 6.97 (d, J=8.5Hz, 2H), 6.73 (s, 1H), 5.23 (s, 2H), 3.80 (s, 2H).
[0430] The activity of the AI-2 quorum sensing inhibitor of the present invention can be detected by the following method
[0431] The inhibition assay of AI-2 quorum sensing by compounds was performed as follows:
[0432] (1) Overnight cultured WHQ01 (S. typhimurium ATCC 202165ΔTolC pWHQ01) or WHQ02 (E. coli BL21ΔTolC pWHQ01) was diluted 1:1000 in fresh LB liquid medium containing 100 μg / mL ampicillin and cultured at 37°C and 220 r / min until the logarithmic growth phase (OD 600 =0.4~0.6).
[0433] (2) Centrifuge the bacterial solution at 3000 × g for 5 minutes, discard the supernatant, dilute with fresh LB liquid medium to 2 McFarland standard and add to a 96-well plate.
[0434] (3) In the experimental group, DMSO solution containing a certain amount of compound was added to make the total volume reach 100 μL.
[0435] (4) The blank group was added with the same volume of DMSO only, and the wells containing 2% w / v glucose and the same volume of DMSO served as the control group.
[0436] (5) After the 96-well plate was shaken and cultured at 37°C and 220 rpm for 3 h, the luminescence and OD values were measured using an Enspire 2300 microplate reader. 600 .
[0437] The inhibition rate calculation formula is as follows:
[0438] Inhibition%=100%×[(XX 对照 ) / (X 空白 -X 对照 )]
[0439] In the formula, X represents the luminescence value of the sample, where X 对照 and X空白 The luminescence values of the control group and the blank group were respectively. The experiment was measured three times in parallel, with three replicates each time. Plasmid pWHQ01 was constructed by cloning the lsr promoter and the luxCDABE fluorescence gene. Therefore, the fluorescence intensity of WHQ01 and WHQ02 is directly regulated by the lsr operon and is positively correlated with the AI-2 quorum sensing intensity.
[0440] The results are shown in Table 1 , and some compounds showed low nanomolar AI-2 quorum sensing inhibitory activity.
[0441] Table 1 IC of AI-2 quorum sensing inhibitors 50 .
[0442] Note: “+” indicates IC 50 <100μM; “++” indicates IC 50 <10μM; “+++” indicates IC 50 <1μM; “++++” indicates IC 50 <0.1μM; "+++++" indicates IC 50 <0.01μM.
[0443]
[0444]
[0445]
[0446]
Claims
1. Compounds of Formula I in, A is an O or S atom; R 1 is a substituted or unsubstituted aromatic carbocyclic ring, aromatic heterocyclic ring, aromatic condensed ring or aromatic heterocondensed ring containing 5 to 10 atoms; wherein the aromatic carbocyclic ring, aromatic heterocyclic ring, aromatic condensed ring or aromatic heterocondensed ring is optionally selected from the following mono- or poly-substituted: substituted or unsubstituted straight-chain or branched alkyl, halogen, cyano, trifluoromethyl, hydroxyl, alkoxy, carboxyl, amino, ester, phosphoester, phosphate; R 2 is a 5- to 8-membered substituted or unsubstituted heterocyclic ring containing O, N, and S atoms; or is a substituted or unsubstituted aromatic heterocyclic ring or aromatic heterocondensed ring containing 5 to 10 atoms; wherein the saturated or unsaturated heterocyclic ring, aromatic heterocyclic ring, and aromatic heterocondensed ring are optionally selected from the following mono- or poly-substituted: substituted or unsubstituted straight-chain or branched alkyl, halogen, cyano, amino, trifluoromethyl, hydroxyl, alkoxy, carboxyl, ester, phosphoester, and phosphate; X 1 is a F, Cl, Br atom, an alkoxy group, an alkyl group of 1 to 3 carbon atoms; X 2 is a F, Cl, Br atom, an alkoxy group, an alkyl group of 1 to 3 carbon atoms; Structural formula I includes its racemate or optical isomer, and pharmaceutically acceptable salts and solvates thereof.
2. The compound of claim 1, wherein the aromatic carbon ring is selected from the group consisting of benzene, naphthalene, anthracene, phenanthrene, indene, fluorene, and acenaphthene.
3. The compound of claim 1, wherein the aromatic heterocycle is selected from the group consisting of pyridine, pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, oxazole, isoxazole, indole, benzofuran, carbazole, pyridazine, pyrazine, quinoline, isoquinoline, purine, phenothiazine, and phenoxazine.
4. A compound according to any one of claims 1 to 3, selected from: 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-1H-1,2,4-triazole N-(4-(Naphthalen-2-ylmethoxy)benzyl)-1-(pyridin-3-yl)methanamine 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-1H-imidazole 1-(4-(Naphthalen-1-ylmethoxy)benzyl)-5-nitro-1H-imidazole N-(4-(Naphthalen-1-ylmethoxy)benzyl)pyrazin-2-amine N-Methyl-N-(4-(naphthalen-2-ylmethoxy)benzyl)pyridin-3-amine 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-5-nitro-1H-imidazole N-(4-(Naphthalen-2-ylmethoxy)benzyl)pyridin-3-amine 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 1-(3-methyl-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole 1-(3-methoxy-4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole 1-(4-((2,4-di-tert-butylbenzyl)oxy)benzyl)-1H-imidazole 1-(4-((3,5-bis(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole 1-(3-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-pyrazole 1-(4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-tetrazolyl 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-tetrazolyl 1-(2-Fluoro-4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-5-carboxylic acid 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid methyl ester 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-5-carboxylic acid 1-(2,3-difluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid 1-(3-fluoro-4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 3-(4-((3-fluoro-5-(trifluoromethyl)benzyl)oxy)benzyl)-4H-4-imidazole-5-carboxylic acid methyl ester 1-(3-Fluoro-4-(perfluorophenyl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(3-fluoro-4-((3-fluoro-3-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((2-bromo-4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((4-fluoronaphthalen-1-yl)methoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-(Cyclohexylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid methyl ester N 1 -(4-(Naphthalen-2-ylmethoxy)benzyl)ethane-1,2-diamine N-(4-(Naphthalen-2-ylmethoxy)benzyl)piperidin-4-amine 1-(4-(Naphthalen-2-ylmethoxy)benzyl)azetidin-3-amine 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid butyl ester 2-(2-methoxyethoxy)ethoxyethyl-1-(4-(naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylate 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid hexan-2-yl ester Isopropyl 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylate 1-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole-4-carboxylic acid propyl ester 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-5-carboxylic acid methyl ester 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid methyl ester 1-(4-((Naphthalen-2-ylmethyl)thio)benzyl)-1H-imidazole-4-carboxylic acid butyl ester 1-(4-((6-bromonaphthalen-2-yl)methoxy)benzyl)-1H-imidazole 1-(4-((6-ethylnaphthyl-2-yl)methoxy)benzyl)-1H-imidazole (1H-imidazol-4-yl)(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)methanol 4-(4-((4-(trifluoromethyl)benzyl)oxy)benzyl)-1H-imidazole 4-(4-(Naphthalen-2-ylmethoxy)benzyl)-1H-imidazole N-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-naphthamide 1-(4-(1-naphthylamino)benzyl)-1H-imidazole-4-carboxylic acid methyl ester Its pharmaceutically acceptable salt or solvate.
5. A pharmaceutical composition comprising at least one compound of formula I according to any one of claims 1 to 4 or a pharmaceutically acceptable salt or hydrate thereof and one or more pharmaceutically acceptable carriers or excipients.
6. Use of the compound according to any one of claims 1 to 5 for preparing a drug for preventing and / or treating diseases caused by bacterial quorum sensing.
7. Use of the compound as claimed in any one of claims 1 to 5 as a drug for treating diseases caused by bacterial infection.
